Business Wire

EuroPCR 2023: Late-Breaking Clinical Data Demonstrate Elixir Medical’s DynamX Bioadaptor Restores Vessel Motion and Function with Better Effectiveness at 12 Months Compared ...

PARIS--(BUSINESS WIRE)--Elixir Medical, a developer of breakthrough cardiovascular technologies, today announced that the large international randomized BIOADAPTOR RCT trial of the company’s DynamX ® ...
Business Wire

EuroPCR 2024: Late-Breaking Data Demonstrate Significant Clinical Advantage of Elixir Medical’s DynamX Bioadaptor Over Standard of Care Drug-Eluting Stent at Two Years

PARIS--(BUSINESS WIRE)--Elixir Medical, a developer of transformative technologies to treat cardiovascular and peripheral disease, today announced two-year results from the BIOADAPTOR Randomized ...
KELOLAND News

EuroPCR 2025: Late-Breaking Data Demonstrate Sustained Significantly Lower Event Rates With Elixir Medical’s DynamX Bioadaptor Over Drug-Eluting Stent Through Three Years

Paris, May 21, 2025 (GLOBE NEWSWIRE) -- —Sustained durability of treatment effect with significantly lower TLF rates (2.7% versus 7.2%, p=0.030) with DynamX ® compared to DES— —Significantly lower ...
News Medical

MXO's dynaMX Compression Staple receives FDA clearance

MX Orthopedics Corp. (MXO) is a privately held company focused on improving implant/bone fixation. MXO is proud to announce the recent FDA clearance (K153129) of the dynaMX™ Compression Staple (patent ...
MarketWatch

EuroPCR 2025: Late-Breaking Data Demonstrate Sustained Significantly Lower Event Rates With Elixir Medical's DynamX Bioadaptor Over Drug-Eluting Stent Through Three Years

The MarketWatch News Department was not involved in the creation of this content. Paris, May 21, 2025 (GLOBE NEWSWIRE) -- --Sustained durability of treatment effect with significantly lower TLF rates ...